Biancalana Lorenzo, Pampaloni Guido, Marchetti Fabio
University of Pisa Dipartimento di Chimica e Chimica Industriale Via Moruzzi 13, I-56124 Pisa, Italy.
Chimia (Aarau). 2017 Sep 27;71(9):573-579. doi: 10.2533/chimia.2017.573.
Ruthenium(II) complexes of formula [Ru(η6-arene)Cl2 (PTA)] (RAPTA) are potential anticancer drugs with notable antimetastatic and antiangiogenic activity, which are now pointing to clinical trials. Following the great interest aroused by these compounds, a variety of RAPTA derivatives, obtained by chloride substitution and/or containing functionalized arene ligands, and complexes resembling the RAPTA structure but bearing different phosphorous ligands have been synthesized and evaluated for their anticancer activity. An overview of all of these biologically relevant complexes will be given, with particular reference to the anticancer behaviour exhibited by the compounds and the possible relationship with structural aspects.
式为[Ru(η6-芳烃)Cl2 (PTA)]（RAPTA）的钌（II）配合物是具有显著抗转移和抗血管生成活性的潜在抗癌药物，目前正指向临床试验。在这些化合物引起极大关注之后，通过氯取代和/或含有功能化芳烃配体获得的各种RAPTA衍生物，以及类似于RAPTA结构但带有不同磷配体的配合物已被合成并评估其抗癌活性。将给出所有这些与生物学相关的配合物的概述，特别提及这些化合物表现出的抗癌行为以及与结构方面可能的关系。
